- Home
- IGC vs NRSN Comparison
IGC vs NRSN Comparison
Compare IGC & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IGC | NRSN |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 29.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IGC | NRSN |
|---|---|---|
| Price | $0.35 | $0.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.13 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 496.5K | 495.3K |
| Earning Date | 11-17-2025 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,106,000.00 | N/A |
| Revenue This Year | $3.54 | N/A |
| Revenue Next Year | $15.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.81 |
| 52 Week High | $0.50 | $2.60 |
Technical Indicators
Market Signals| Indicator | IGC | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 37.38 |
| Support Level | $0.28 | $0.86 |
| Resistance Level | $0.36 | $1.24 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 86.10 | 7.89 |
Price Performance
Historical ComparisonAbout IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.